Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 10.8% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics (NTLA) is a biotechnology company focused on developing CRISPR/Cas9-based gene editing therapies. Today, NTLA experienced a strong bullish movement in the stock market.

Why is Intellia Therapeutics, Inc. going up?

NTLA stock is up 10.8% on Apr 30, 2026 14:15

• NTLA's stock surged after announcing the pricing of a public offering, raising significant gross proceeds and indicating investor confidence in the company's future prospects.
• The successful results of the Phase 3 trial for lonvo-z, Intellia's gene-editing medicine for hereditary angioedema (HAE), played a crucial role in driving up the stock price.
• The initiation of a rolling Biologics License Application submission to the FDA and the anticipation of a potential U.S. launch in the first half of 2027 further fueled positive investor sentiment.
• Overall, the combination of successful trial data, regulatory progress, and strong financial backing contributed to NTLA's bullish market movement today.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

Intellia Therapeutics, Inc. announced the pricing of an underwritten public offering of 16,744,187 shares of its common stock at $10.75 per share, expecting to raise approximately $180 million in gross proceeds. The company has also granted underwriters a 30-day option to purchase an additional 2,511,628 shares. Jefferies, Goldman Sachs & Co. LLC, and Citigroup are acting as joint book-running managers for the offering.

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-pricing-public-offering-common-4

Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder

Intellia Therapeutics' experimental gene-editing medicine, lonvo-z, successfully met its primary objective in a Phase 3 trial for hereditary angioedema (HAE), reducing swelling attacks by 87% compared to placebo. This positions Intellia to seek approval for what would be the first in vivo gene-editing treatment for HAE, despite ongoing investor skepticism about its commercial potential in a market with existing effective therapies. The therapy showed a "favorable" safety profile, and the company plans a U.S. approval submission, aiming for a launch in the first half of 2027.

https://www.biopharmadive.com/news/intellia-gene-editing-hereditary-angioedema-lonvo-z-results/818503/

NTLA Jumps Premarket On Positive Late-Stage Trial Data For Gene-Editing Therapy — Retail Says Buy Now Before It’s Too Late

Intellia Therapeutics (NTLA) shares surged pre-market following positive late-stage trial data for its gene-editing therapy, lonvoguran ziclumeran (lonvo-z), for hereditary angioedema (HAE). The therapy met primary and secondary endpoints, with 62% of patients free of HAE attacks, compared to 11% on placebo. Intellia has initiated a rolling Biologics License Application submission to the FDA and aims for a U.S. launch in the first half of 2027.

https://stocktwits.com/news-articles/markets/equity/ntla-stock-soars-intellia-positive-gene-therapy-trial/cZBNFouRe2C

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

Intellia Therapeutics announced positive topline results from its global Phase 3 HAELO clinical trial for lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE), marking the first Phase 3 data for an in vivo gene editing therapy. The trial met its primary and all key secondary endpoints, demonstrating that a single dose of lonvo-z significantly reduced HAE attacks and freed most patients from ongoing therapy for six months. Intellia has initiated a rolling Biologics License Application (BLA) submission with the U.S. FDA, anticipating a potential U.S. launch in the first half of 2027 if approved.

https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-reports-positive-phase-3-results

Intellia Therapeutics Initiates Rolling Submission of

Intellia Therapeutics has begun a rolling submission of a biologics license application (BLA) to the FDA for lonvoguran ziclumeran (lonvo-z), a one-time gene-editing treatment for hereditary angioedema (HAE). This submission follows positive Phase 3 HAELO trial results, which showed lonvo-z freed most patients from HAE attacks and ongoing therapy. The company expects to complete the BLA by the second half of 2026 and, if approved, plans a commercial launch in the first half of 2027.

https://www.globenewswire.com/news-release/2026/04/27/3281478/0/en/intellia-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-lonvoguran-ziclumeran-lonvo-z-as-a-one-time-treatment-for-hereditary-angioedema.html

Trending Today

Roku Inc. ($ROKU) Stock Forecast: Up 5.1% Today

Twilio Inc. Class A ($TWLO) Stock Forecast: Up 5.2% Today

eBay Inc. ($EBAY) Stock Forecast: Up 6.2% Today

Texas Instruments Incorporated ($TXN) Stock Forecast: Up 5.3% Today

Eli Lilly and Company ($LLY) Stock Forecast: Up 9.7% Today

Altria Group Inc. ($MO) Stock Forecast: Up 6.0% Today

Bristol-Myers Squibb Company ($BMY) Stock Forecast: Up 5.1% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 6.0% Today

O'Reilly Automotive Inc. ($ORLY) Stock Forecast: Up 8.7% Today

IPG Photonics Corporation ($IPGP) Stock Forecast: Up 5.4% Today

Intellia Therapeutics, Inc. Price History

27.03.2026 - NTLA Stock was down 5.1%

• NTLA stock had a bearish movement despite positive late-stage trial data for its gene-editing therapy for hereditary angioedema (HAE).
• The market may have reacted negatively due to profit-taking by investors who were anticipating a bullish run following the positive trial results.
• Despite the positive news, the stock might have been impacted by the overall market sentiment or profit concerns, leading to the bearish movement.
• It's essential to consider that short-term market fluctuations do not always reflect the long-term potential of a company's innovative therapies.

31.02.2026 - NTLA Stock was up 5.2%

• Despite receiving a "Hold" rating from most brokerages, Intellia Therapeutics experienced a significant uptrend after being upgraded to a "strong-buy" by Truist Financial.
• The gene editing sector, including Intellia Therapeutics, faced a downtrend, possibly influencing the stock price initially.
• Intellia Therapeutics' recent strong earnings report, surpassing expectations, likely boosted investor confidence in its performance.
• The internal reshuffling of Vanguard's holdings, resulting in share disaggregation, may have caused some uncertainty but did not have a direct impact on the stock movement.

29.03.2026 - NTLA Stock was down 10.0%

• Despite favorable late-stage trial outcomes and starting the FDA submission process for lonvoguran ziclumeran (lonvo-z) for HAE treatment, NTLA witnessed a decline in its stock value.
• The decrease in share price due to a public stock offering priced lower per share raised concerns about potential dilution among investors, impacting the company's stock performance negatively.
• Market sentiment may have been influenced by fears of share dilution from the public offering, overshadowing the encouraging trial results and future potential of gene-editing therapies.
• Investor hesitancy regarding the company's fundraising strategies and their effects on current shareholders prompted selling pressures, despite promising advancements in clinical research.

22.03.2026 - NTLA Stock was up 6.6%

• Analysts have given NTLA a moderate buy rating with an average price target of $21.25, indicating positive sentiment towards the company's future prospects.
• Despite recent share price volatility, the company's strong year-to-date and one-year performance, along with a narrative of rapid revenue growth, have contributed to the bullish movement.
• The market's interest in NTLA's valuation, driven by demographics and genetic conditions supporting its value, coupled with potential risks from trial disappointments or payer pushback, may have influenced the positive market sentiment.
• The amendment of by-laws and designation of federal district courts as the exclusive forum for Securities Act claims could also be seen as a positive development, enhancing shareholder rights and potentially boosting investor confidence in the stock.

05.02.2026 - NTLA Stock was down 5.1%

• The bearish movement in NTLA stock today could be attributed to profit-taking by investors after a recent surge in the stock price.
• Actions impacting GLP-1 compounders by the FDA might have raised concerns about regulatory scrutiny in the biotech sector, negatively affecting NTLA's stock.
• Despite positive clinical news and increased stake by Vanguard Group Inc., the overall market sentiment towards biotech companies like Intellia might have been affected by the uncertainty surrounding FDA actions and regulatory compliance.
• Insider sales at Intellia, the company's pre-revenue status, and negative margins could have also contributed to the bearish sentiment among investors.

19.02.2026 - NTLA Stock was down 5.4%

• Farallon Capital Management LLC acquired a significant number of shares in NTLA, indicating confidence in the company's potential.
• Despite reporting better-than-expected earnings and surpassing analyst revenue estimates, company insiders have been selling shares in the last ninety days.
• The increased holdings by institutional investors may have contributed to the downward pressure on NTLA's stock price.
• The bearish movement could be a result of profit-taking by insiders or concerns about the sustainability of NTLA's recent positive performance.

21.03.2026 - NTLA Stock was up 6.2%

• NTLA stock saw a positive trend today, possibly influenced by its strong year-to-date and one-year performance, as well as favorable analyst target prices and valuation models.
• The market shows confidence in NTLA's potential for revenue growth and its capacity to meet the increasing demand for genetic therapies.
• Despite risks like disappointing trial outcomes or cost challenges, investors are currently drawn to NTLA because of its promising future and valuation indicators.

25.02.2026 - NTLA Stock was up 5.3%

• The rise in NTLA's stock price might be due to positive sentiment from AI models suggesting short-term strength and the adoption of potential institutional trading strategies.
• Despite recent selling by Hudson Bay Capital Management LP and company insiders, the stock surpassed Q3 revenue and EPS estimates, indicating solid fundamentals.
• A possible securities class action lawsuit alleging lack of disclosure on the inefficiency of the NTLA-3001 program initially led to a stock price decline, but investors appear hopeful about the company's future prospects.
• In summary, the surge in Intellia Therapeutics' stock price today could be driven by a blend of positive sentiment, exceeding financial expectations, and potential institutional trading strategies.

24.03.2026 - NTLA Stock was down 10.3%

• The bearish movement in NTLA stock today could be attributed to the following factors:
• Despite the recent positive momentum and market leadership demonstrated by Intellia Therapeutics, investors might be taking profits after a significant 20% increase in the stock price over the past three months.
• The mixed short-term returns and recent share price volatility, coupled with potential risks such as disappointing trial results or payer pushback on costs, could be causing some uncertainty among investors.
• While analysts have provided a moderate buy rating and set an average price target of $21.25, the discrepancy between the current share price and the estimated fair value according to a DCF model might be contributing to the downward pressure on the stock.
• Investors may also be cautious due to the company's amendment of its by-laws and the designation of federal district courts as the exclusive forum for Securities Act claims, which could introduce legal uncertainties impacting the stock's performance.

13.03.2026 - NTLA Stock was up 5.9%

• Intellia Therapeutics (NTLA) saw a significant increase of 14.2% in its stock price today.
• The rise in stock price is linked to the FDA lifting clinical holds on Intellia's MAGNITUDE trials, which has provided regulatory clarity and bolstered investor confidence.
• An analyst upgrade from Jones Trading further boosted optimism about Intellia, emphasizing the potential of its gene editing programs for conditions like ATTR amyloidosis and HAE.
• The market is reflecting expectations for future growth for Intellia, as evidenced by its high Price/Sales ratio, indicating positive outlook on the company's prospects in the gene editing industry.

30.03.2026 - NTLA Stock was up 10.8%

• NTLA's stock surged after announcing the pricing of a public offering, raising significant gross proceeds and indicating investor confidence in the company's future prospects.
• The successful results of the Phase 3 trial for lonvo-z, Intellia's gene-editing medicine for hereditary angioedema (HAE), played a crucial role in driving up the stock price.
• The initiation of a rolling Biologics License Application submission to the FDA and the anticipation of a potential U.S. launch in the first half of 2027 further fueled positive investor sentiment.
• Overall, the combination of successful trial data, regulatory progress, and strong financial backing contributed to NTLA's bullish market movement today.

11.02.2026 - NTLA Stock was down 7.9%

• Despite promising long-term data for its HAE candidate and FDA approval for its ATTR-CM therapy, concerns persist among investors regarding ongoing losses, liver safety issues, and lengthy path to profitability.
• The participation in the Leerink Global Healthcare Conference could give the company a chance to address investor worries and clarify its strategic outlook.
• The stock price surge following the FDA's removal of clinical holds on its gene-editing drug nex-z reflects investor confidence, although safety concerns and high costs of gene-editing therapies remain.
• NTLA is deemed undervalued compared to its fair value estimate, indicating that investors, despite recent positive developments, are still wary of potential clinical hurdles or slow therapy adoption that could impact future performance.